Angel Yeast Co., has developed a new strain of yeast probiotic, Saccharomyces boulardii Bld-3 (S. boulardii Bld-3), designed to treat diarrhoea and strengthen healthy digestive and immune systems in children and adults.
“The new strain of yeast probiotic developed by Angel Nutrition & Health Technical Center, S. boulardii Bld-3, is another ground-breaking addition to the S. boulardii family that has been proven effective in speeding up recovery from acute diarrhoea and is beneficial to intestinal health in the long term,” said Dr Zhang Yan, chief technical officer of Angel Nutritech.
COVID-19 has prompted more people to pay attention to their health and an increased focus on precautionary measures and healthcare products that prevent diseases and support their immune systems. Keyword searches related to probiotics also climbed to a record high this year.
The use of S. boulardii in managing diarrhoea in adults and children has been widely prescribed by doctors and gastroenterologists for decades. Its efficacy for combating an array of gastrointestinal conditions is well-documented too.
Angel’s S. boulardii Bld-3 is developed using the low-temperature fluidised bed process. The company’s unique protection technology allows it to quickly form a dense yeast shell that encloses active yeast probiotics entrapped inside. This process strengthens the yeast’s resistance to gastric acid and bile salts, enabling it to be applied in a wide variety of end probiotic products.
Angel’s S. boulardii Bld-3 is a suitable ingredient for wide-ranging probiotic dietary supplements. Thanks to the larger size of yeast probiotics, which is 10 times as big as that of Lactobacillus probiotics, they are more likely to form a space-occupying effect in the intestinal tract and are resistant to antibiotics.
In addition to S. boulardii Bld-3, Angel Yeast also produces Saccharomyces cerevisiae probiotic and other extensive ranges of functional yeast ingredients, with several new products in the pipeline including Kluyveromyces marxianus.